UK’s CMA Doubles Down On Liothyronine Objections

Following Ruling On Unfair Pricing For Phenytoin In March

 
• By David Wallace
  
Pills_GBP
The CMA insists Advanz charged excessive and unfair UK prices for liothyronine • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Regulation

More from Policy & Regulation